Risk of Chronic Kidney Disease Progression

NCT02654756 | Completed

• 1 other identifier: 13311
• Study Type: observational
• Target: 623
• Locations: 1 country
• Sites: 1

Brief Summary

While there are proven therapies that slow CKD progression, these therapies can at times be harmful and costly. The ability to accurately predict the risk of CKD progression to ESRD would be extremely valuable. The short term versus lifetime risk of CKD progression should be taken into account when making risk based clinical decisions. In a representative CKD practice, the investigators compared the short term and lifetime risk assessment in our stage 3 CKD patients to determine whether decisions based on a short term risk assessment would underestimate the lifetime risk of CKD progression. The investigators also applied the short term risk assessment to our stage 4 CKD patients to determine the frequency with which ESRD risk may be overestimated in CKD stage 4.

Conditions

Chronic Kidney Disease; End Stage Renal Disease

Keywords

Risk Assessment

Outcome Measures

Primary Outcomes (2)

• Percentage difference in risk levels when comparing short term risk and lifetime risk in patients with CKD stage 3.

  2 to 5 years

• Percentage of patients with CKD stage 4 in low, intermediate and high risk categories after assessing short term risk in patients with CKD stage 4.

  2 to 5 years

Secondary Outcomes (1)

• Assessment ESRD outcomes after risk stratification.

  2 to 5 years

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Nephrology outpatient clinic

You may qualify if:

• Evaluation at least once by a nephrologist in the past year.
• Subjects must have recent pertinent laboratory data within the last 2 years.
• documented creatinine values separated by at least 3 months

You may not qualify if:

• Deceased patients
• estimated GFR \< 15ml/min
• Patients with Acute Renal Failure (ARF)

Sponsors & Collaborators

• Winthrop University Hospital: lead

Study Sites (1)

NYU Winthrop

Mineola, New York, 11501, United States

Location

MeSH Terms

Conditions

Renal Insufficiency, Chronic; Kidney Failure, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Candace Grant, MD

  NYU Winthrop

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 11, 2016
• First Posted: January 13, 2016
• Study Start: May 1, 2013
• Primary Completion: November 1, 2018
• Study Completion: November 1, 2018
• Last Updated: February 21, 2023

Record last verified: 2023-02

Locations

US (1)